Research Article

Analysis of the Efficacy and Pharmacological Mechanisms of Action of Zhenren Yangzang Decoction on Ulcerative Colitis Using Meta-Analysis and Network Pharmacology

Guosheng Xing,1,2 Yufeng Zhang,3 Xinlin Wu,2 Hua Wang,2 Yan Liu,4 Zhen Zhang,1,2 Mingxing Hou1,2 and Haibing Hua5

1Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210008, China
2Department of General Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, China
3Department of Respiratory Medicine, Jiangyin Hospital of Traditional Chinese Medicine, Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin, Jiangsu 214400, China
4Department of Traditional Chinese Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, China
5Department of Gastroenterology, Jiangyin Hospital of Traditional Chinese Medicine, Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin, Jiangsu 214400, China

Correspondence should be addressed to Mingxing Hou; 15354878601@163.com and Haibing Hua; hhbjytcm@163.com

Received 31 August 2021; Revised 20 November 2021; Accepted 13 December 2021; Published 28 December 2021

Academic Editor: Lifeng Han

Copyright © 2021 Guosheng Xing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. We analyzed the efficacy and pharmacological mechanisms of action of Zhen Ren Yang Zang decoction (ZRYZD) on ulcerative colitis (UC) using meta-analysis and network pharmacology. Methods. The major databases were searched for randomized controlled trials of ZRYZD for the treatment of UC. Meta-analysis of the efficacy of ZRYZD on UC was conducted using RevMan software. Active compounds and target genes were acquired using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. UC-related genes were searched using the GeneCards database. Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using RGUI. A compound-target network was constructed using Cytoscape software, and a protein-protein interaction network was constructed using the STRING database. Molecular docking simulations of the macromolecular protein targets and their corresponding ligand compounds were performed using the AutoDock tool and AutoDock Vina software. Results. Meta-analysis revealed that the total effective rate and recovery rate of clinical efficacy were significantly higher in the experimental group than those of the control group. The screening identified 169 active compounds and 277 active target genes for ZRYZD. The 277 active target genes were compared with the 4,798 UC-related genes. This identified 187 active target genes of ZRYZD for UC that correlated with 138 active compounds. GO functional enrichment and KEGG pathway enrichment analyses were performed, and compound-target and protein-protein interaction networks were constructed. The key compounds and key target proteins were then selected. Finally, target protein binding with the corresponding compound was analyzed using molecular docking. Conclusion. Our findings demonstrate the effectiveness and safety of ZRYZD for the treatment of UC and provide insight into the underlying pharmacological mechanisms of action. Furthermore, key compounds were identified, laying the foundation for future studies on ZRYZD for the treatment of UC.
1. Introduction

Ulcerative colitis (UC) is a common chronic intestinal disease of unknown etiology and is associated with multifactorial, multilevel, and nonspecific inflammation [1]. The clinical manifestations of UC include diarrhea, abdominal pain, and stool containing mucus, pus, and/or blood. The incidence of UC is 1.2–20.3 per 100,000 persons per year, and its prevalence is 7.6–246.0 per 100,000 per year [2].

The lesions in UC involve the rectum and sigmoid colon, sometimes throughout the whole colon, mainly invading the colorectal mucosa and submucosa and showing phased and diffuse distribution, resulting in a propensity for relapse [3]. Mesalazine, immunosuppressants, and corticosteroids are clinically used to treat UC; however, these drugs are needed chronically and can cause adverse reactions, and relapse is common after cessation [4, 5]. Traditional Chinese medicine (TCM) has a long history of treating diarrhea and dysentery and is compliant with the concept of individualized treatment [6]. Recently, TCM has been used to treat UC, with positive outcomes [7–9].

Zhen Ren Yang Zang decoction (ZRYZD), first used during the Song Dynasty as the basic prescription for the treatment of diarrhea, primarily consists of yingsuke, rou doukou, hezi, rougui, dangshen, baizhu, danggui, baishao, muxiang, and gancao (scientific names: *Pericarpium Papaveris* (PP), *Semen Myristicae* (SM), *Fructus Chebulic* (FC), *Cortex Cinnamomi* (CC), *Radix Codonopsis* (RC), *Rhizoma Atractyloidis Macrocephalae* (RAM), *Radix Angelicae Sinensis* (RAS), *Radix Paoniae Alba* (RPA), *Radix Aucklandiae* (RA), and *Radix Glycyrrhizae* (RG), respectively) [10]. According to TCM theory, PP, SM, and FC are monarch and minister herbs and are regarded as the main components of ZRYZD.

ZRYZD acts as an intestinal astringent, has antidiarrheal properties, and warms the spleen and kidney. Several clinical studies have reported that the clinical effect of ZRYZD in the treatment of UC is remarkable [10–12]. Previous basic research studies suggest that ZRYZD can ameliorate colonic mucosal dysfunction and that it has a favorable therapeutic action in trinitrobenzenesulfonic acid-induced colitis [13]. Therefore, the clinical efficacy and pharmacology of ZRYZD for the treatment of UC merit further investigation.

In this study, we analyzed the efficacy and pharmacological mechanisms of action of ZRYZD for the treatment of UC using meta-analysis and network pharmacology. First, we screened randomized controlled trials (RCTs) that investigated the clinical efficacy of ZRYZD for UC and performed a meta-analysis to assess clinical efficacy and safety. Next, we identified the active compounds in ZRYZD and its target genes and compared them with UC-related genes to identify the active target genes involved in the therapeutic action of ZRYZD for UC. Subsequently, Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. The compound-target, key compound-target, and protein-protein interaction (PPI) networks were constructed, and the key compounds and key target proteins were selected. Finally, target protein binding with the corresponding compound was analyzed using molecular docking analysis.

2. Materials and Methods

2.1. Screening of RCTs of the Efficacy of ZRYZD in the Treatment of UC. PubMed, the Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, Wanfang Data, the Chongqing VIP database, and the Chinese Biomedical Literature database, from the establishment of each database to August 15, 2021, were searched using the terms “Zhen Ren Yang Zang decoction” and “ulcerative colitis.” These terms were searched in titles, abstracts, and the full text. We also checked references and citations in the identified studies manually to include other potentially eligible trials until no additional articles could be identified.

The inclusion criteria included the following: the study was designed as a RCT, the participants had a diagnosis of UC, ZRYZD was used in the experimental group, the control group used conventional therapy without TCM therapy, and there were clear outcome indicators. Exclusion criteria included the following: the outcome data of the study were incomplete and the ZRYZD prescription lacked the main components.

2.2. Data Extraction, Quality Assessment, and Meta-Analysis. Two reviewers independently extracted the information from the included studies. The main information included the first author, year of publication, number of patients in each group, methods of intervention in the experimental and control groups, and outcome data.

The Cochrane Reviewers’ Handbook of guidelines was used to assess the risk of bias. The following seven criteria were used: random sequence generation; allocation concealment; patient blinding; assessor blinding; incomplete outcome data; selective outcome reporting; other risks of bias [14].

These main data were input into the Cochrane Collaboration’s RevMan 5.3 software for meta-analysis to analyze the efficacy of ZRYZD on UC.

2.3. Screening of Active Compounds in ZRYZD. The compounds in the ten component herbs (PP, SM, FC, CC, RC, RAM, RAS, RPA, RA, and RG) were obtained using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) (https://tcmspwww.com/tcmsphp) [15]. TCMSP is a unique systems pharmacology platform of Chinese herbal medicines that captures the relationships between drugs, targets and diseases. Oral bioavailability (OB) and drug-likeness (DL) are commonly used in network pharmacology to define active compounds. OB represents the rate the compound is absorbed into the body, and DL represents the degree to which a compound contains specific functional groups or has physical characteristics similar to existing drugs [16]. We used OB ≥ 30% and DL ≥ 0.18 to screen for the active compounds (the DLs of compounds in CC are generally low, and we, therefore, set DL ≥ 0.10 as the filter criteria) [17].
2.4. Screening of the Target Genes of Active Compounds. The corresponding target genes of the active compounds were also retrieved from the TCMSP. Setting the search format as “homo sapiens,” the target genes were imported into the UniProt Knowledgebase, a comprehensive resource for protein sequences and annotation data (https://www.uniprot.org/) [18]. Then, the human official gene symbols were identified and were considered the active target genes of ZRYZD.

2.5. Acquisition of UC-Related Genes and Identification of Active Target Genes of ZRYZD Acting on UC. “Ulcerative colitis” was used as the keyword in the GeneCards database (https://www.genecards.org/). The GeneCards database is a searchable, integrative database providing comprehensive, user-friendly information on all annotated and predicted human genes [19], from which the UC-related genes were searched and acquired. Then, the active target genes of ZRYZD were compared with the UC-related genes, and the intersecting genes were defined as the active target genes of ZRYZD acting on UC.

2.6. GO Functional Enrichment and KEGG Pathway Enrichment Analyses. The RGUI 3.6.1 and org.Hs.eg.db packages were used to obtain the entrezIDs of the active target genes. Then, RGUI and the clusterProfiler package were used to perform the GO functional enrichment analyses, which included the biological process (BP), molecular function (MF), cellular component (CC) analysis, and the KEGG pathway enrichment analysis [20].

2.7. Construction of the Compound-Target Network. Cytoscape 3.6.0 software and its NetworkAnalyzer tool function were used to construct and analyze the compound-target network. Nodes represent compounds and target genes, and edges represent the relationships between them. According to the degree of connection between the compound and the target gene (the more the connections, the higher the degree value), the compounds and target genes in the network were subject to further analysis [21].

2.8. Construction of the PPI Network. A PPI network was constructed after introducing the active target genes into the STRING database. The STRING database supports functional discovery in genome-wide experimental datasets (https://string-db.org/) [22]. Defining the research species as “homo sapiens” and the lowest interaction score of 0.4, a PPI network was obtained. Then, the PPI network data were used to perform topology analysis, and the key target proteins of ZRYZD acting on UC were selected according to the degree values of each target protein (the more the connections, the higher the degree value) using Cytoscape 3.6.0 software and its NetworkAnalyzer tool [21].

2.9. Verification of Molecular Docking. The binding of the target protein with its corresponding compound was analyzed using molecular docking. The structures of the target proteins were obtained from the RCSB PDB database (https://www.rcsb.org/), and the compounds were obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Molecular docking simulations of target proteins with their corresponding compounds were performed using AutoDockTool 1.5.6 and AutoDock Vina software [23, 24].

2.10. Statistical Analysis. RevMan 5.3 software was used for meta-analysis, and dichotomous data were expressed as the odds ratio (OR) with 95% confidence interval (CI), and continuous data were expressed as mean difference (MD) with 95% CI. Heterogeneity was assessed with the Q-test ($P$-value and $I^2$), and $P<0.10$ indicated heterogeneity across studies. Studies with $I^2<50\%$ were considered to have no heterogeneity, and those with $I^2 \geq 50\%$ were considered to have heterogeneity. If no heterogeneity was detected, the fixed effects model was used as the pooling method; otherwise, the random effects model was used [25, 26]. $P<0.05$ was considered statistically significant.

Using the bioinformatics tools of the platforms and software mentioned above, some statistical analyses for network pharmacology were performed automatically. In the GO functional enrichment and KEGG pathway enrichment analyses, an adjusted $P$ ($q$-value) $<0.05$ was considered statistically significant.

3. Results

3.1. Screened RCTs Investigating the Efficacy of ZRYZD for the Treatment of UC. A total of 118 studies were retrieved through database searching, and 36 studies were retained after removing duplication. According to the inclusion and exclusion criteria, a total of 31 studies were excluded after reading the title, abstract, and full text. Five RCTs [11, 12, 27–29] were included for further evaluation. The literature screening process is shown in Figure 1.

3.2. Description of Included RCTs and Assessment of the Methodological Quality. Five eligible RCTs [11, 12, 27–29] were identified. The five RCTs were all conducted in China and included 356 patients. The five studies were all single-center studies. The basic features of the included studies are outlined in Table 1.

One RCT [28] employed the odd and even numbers method of random sequence generation; none of the RCTs introduced allocation concealment; none of the RCTs described blindness; all the RCTs had complete outcome data; and for all studies, we were unable to determine whether they selectively reported data (Table 2, Figures S1 and S2).

Four RCTs [11, 12, 27, 28] assessed the total effective rate of clinical efficacy, four RCTs [11, 12, 27, 28] assessed the recovery rate of clinical efficacy, and one RCT [12] assessed the recovery rate of clinical efficacy. One RCT [28] evaluated the serum cytokines interleukin-6 (IL-6) and IL-8 and tumor necrosis factor-α (TNF-α), and one RCT [29] evaluated serum IL-6 and TNF-α. Two RCTs [28, 29] analyzed the total syndrome score of TCM, one RCT [28] assessed diarrhea,
Figure 1: Flowchart of the study selection process.

Table 1: Summary of RCTs of ZRYZD for UC.

| Study year [ref] | Country | Sample size (experimental/control) | Mean age (years) | Experimental | Control | Duration |
|------------------|---------|-----------------------------------|-----------------|--------------|---------|----------|
| Yuan JY, 2009 [11] | China   | 88 (44/44)                        | 35.4/33.6       | ZRYZD        | SASP    | 6 months |
| Zhao KH, 2010 [12] | China   | 35 (19/16)                        | 39.8 ± 14.0/40.2 ± 15.0 | ZRYZD        | SASP    | 6 months |
| Wang L, 2015 [27]  | China   | 80 (40/40)                        | 33.4/34.6       | ZRYZD        | SASP    | 4 weeks  |
| Han Y, 2019 [28]   | China   | 63 (32/31)                        | 38.7 ± 7.9/36.6 ± 9.2 | ZRYZD        | Mesalazine bowel-soluble tablets | 6 weeks |
| Dai AC, 2021 [29]  | China   | 90 (45/45)                        | 39.8 ± 3.16/39.91 ± 3.22 | ZRYZD        | Mesalazine bowel-soluble tablets | 6 weeks |

RCT: randomized controlled trial; ZRYZD: Zhen Ren Yang Zang decoction; UC: ulcerative colitis; SASP: sulfasalazine.

Table 2: Risk of bias in the five included RCTs.

| Study year[ref] | Random sequence generation | Allocation concealment | Blinding of patient | Blinding of assessor | Incomplete outcome data | Selective reporting | Other bias |
|------------------|-----------------------------|-----------------------|---------------------|----------------------|------------------------|---------------------|-----------|
| Yuan JY, 2009 [11] | U                           | U                     | H                   | H                    | L                      | U                   | L         |
| Zhao KH, 2010 [12] | U                           | U                     | H                   | H                    | L                      | U                   | L         |
| Wang L, 2015 [27]  | U                           | U                     | H                   | H                    | L                      | U                   | L         |
| Han Y, 2019 [28]   | H                           | U                     | H                   | H                    | L                      | U                   | L         |
| Dai AC, 2021 [29]  | U                           | U                     | H                   | H                    | L                      | U                   | L         |

RCT: randomized controlled trial; L: low risk of bias; H: high risk of bias; U: unclear (uncertain risk of bias).
abdominal pain, mucopurulent bloody stool, and tenesmus score, and one RCT [28] compared Sutherland disease activity indexes. Adverse reactions were mentioned in three studies [11, 28, 29], while the other two studies [12, 27] did not mention whether there were adverse reactions. The main outcomes and results are presented in Table 3.

3.3. Meta-Analysis

3.3.1. Clinical Efficacy. The four studies [11, 12, 27, 28] that compared the total effective rate of clinical efficacy included a total of 266 participants—135 in the experimental groups and 131 in the control groups. The four studies showed homogeneity of the data (heterogeneity test, $\chi^2 = 0.37, P = 0.95, I^2 = 0\%$). When the fixed effects model was used to merge MD values, the pooled MD was $-2.98$ [95% CI $(-3.73)–(-2.23)$, $Z = 7.81, P < 0.0001$]. This indicated that the total syndrome score of TCM was significantly lower in the experimental group than that in the control group (Figure S4).

3.3.2. Serum Cytokines. The two studies [28, 29] that compared serum TNF-α included a total of 153 participants—77 in the experimental group and 76 in the control group. The two studies showed homogeneity (heterogeneity test, $\chi^2 = 2.76, P = 0.43, I^2 = 0\%$). When the fixed effects model was used to merge OR values, the pooled OR was $3.11$ [95% CI $1.50–6.46, Z = 3.05, P = 0.002$]. This indicated that the total effective rate of clinical efficacy was significantly higher in the experimental group than that in the control group (Figure 2(a)).

The four studies [11, 12, 27, 28] that compared the recovery rate of clinical efficacy included a total of 266 participants—135 in the experimental groups and 131 in the control groups. The four studies showed homogeneity (heterogeneity test, $\chi^2 = 1.53, P = 0.22, I^2 = 35\%$). When the fixed effects model was used to merge MD values, the pooled MD was $-15.74$ [95% CI $(-17.95)–(-13.53), Z = 13.96, P < 0.0001$]. This indicated that serum IL-6 was significantly lower in the experimental group than that in the control group (Figure S3A).

The two studies [28, 29] that compared serum TNF-α included a total of 153 participants—77 in the experimental group and 76 in the control group. The two studies showed homogeneity (heterogeneity test, $\chi^2 = 0.23, P = 0.64, I^2 = 0\%$). When the fixed effects model was used to merge MD values, the pooled MD was $-26.21$ [95% CI $(-29.37)–(-23.05), Z = 16.25, P < 0.00001$]. This indicated that serum TNF-α was significantly lower in the experimental group than that in the control group (Figure S3B).

3.3.3. Syndrome Scores of TCM. The two studies [28, 29] that compared the total syndrome score TCM included a total of 153 participants—77 in the experimental group and 76 in the control group. The two studies showed heterogeneity (heterogeneity test, $\chi^2 = 2.45, P = 0.12, I^2 = 59\%$). When the random effects model was used to merge MD values, the pooled MD was $-2.98$ [95% CI $(-3.73)–(-2.23), Z = 7.81, P < 0.0001$]. This indicated that the total syndrome score of TCM was significantly lower in the experimental group than that in the control group (Figure S4).

3.3.4. Adverse Reactions. The three studies [11, 28, 29] that compared the incidence of adverse reactions included a total of 241 participants—121 in the experimental group and 120 in the control group. The three studies showed homogeneity of the data (heterogeneity test, $\chi^2 = 0.03, P = 0.87, I^2 = 0\%$). When the fixed effects model was used to merge OR values, the pooled OR was $0.12$ [95% CI $0.03–0.54, Z = 2.76, P = 0.006$]. This indicated that the incidence of adverse reactions was significantly lower in the experimental group than in the control group (Figure 3).

3.4. Screening of Active Compounds in ZRYZD. A total of 24 compounds were obtained from PP, 64 from SM, 41 from FC, 100 from CC, 134 from RC, 55 from RAM, 125 from RAS, 85 from RPA, 106 from RA, and 280 from RG using the TCMSP (Supplementary File 1). By setting the filter criteria as OB ≥ 50% and DL ≥ 0.18, 11 active compounds from PP, 9 from SM, 8 from FC, 10 from CC (setting DL ≥ 0.10), 21 from RC, 7 from RAM, 2 from RAS, 13 from RPA, 6 from RA, and 92 from RG were obtained. Finally, 169 active compounds in ZRYZD remained after the exclusion of duplicates. The basic information on the active compounds in ZRYZD is shown in Table S1.

3.5. Screened Active Target Genes of ZRYZD. The corresponding target genes of the 169 active compounds were also obtained from the TCMSP, in which 19 compounds did not have corresponding targets. Then, the corresponding gene symbols were screened by setting the format as "homo sapiens" from the UniProt Knowledgebase. Finally, 277 active target genes of the 150 active compounds in ZRYZD were identified (Supplementary File 2).

3.6. Acquired UC-Related Genes and Identified Active Target Genes of ZRYZD Acting on UC. We used "ulcerative colitis" as the keyword to search in the GeneCards database, which retrieved 4,798 UC-related genes (Supplementary File 3). The 277 active target genes of ZRYZD were compared with the 4,798 UC-related genes, which identified 187 active target genes of ZRYZD acting on UC (Figure 4, Table S2).

3.7. GO Functional Enrichment and KEGG Pathway Enrichment Analyses. The entrezIDs of the active target genes of ZRYZD acting on UC were obtained using RGUI and org.Hs.eg.db (Table S2). Then, GO functional enrichment and KEGG pathway enrichment analyses were performed using RGUI and clusterProfiler.

The GO BP functional enrichment analysis showed that the active target genes of ZRYZD acting on UC were significantly enriched in cellular response to chemical stress, response to lipopolysaccharides, response to molecules of
Table 3: Main outcomes in the included RCTs.

| Study year [ref] | Main outcomes | Main results (effect size) | Adverse events |
|------------------|---------------|---------------------------|---------------|
| Yuan JY, 2009 [11] | (1) Clinical efficacy | Total effective rate: OR, 3.32 [0.63, 17.43]; Recovery rate: OR, 3.10 [1.24, 7.79]; Recurrence rate: OR, 0.18 [0.05, 0.61] | No adverse reactions |
| Zhao KH, 2010 [12] | (1) Clinical efficacy | Total effective rate: OR, 4.15 [0.39, 44.57]; Recovery rate: OR, 2.86 [0.72, 11.31] | n.r. |
| Wang L, 2015 [27]  | (1) Clinical efficacy | Total effective rate: OR, 2.43 [0.81, 7.30]; Recovery rate: OR, 8.22 [2.16, 31.27] | n.r. |

RCT: randomized controlled trial; TCM: traditional Chinese medicine; IL: interleukin; TNF: tumor necrosis factor; OR: odds ratio; MD: mean difference; n.r.: not reported.

bacterial origin, response to oxidative stress, response to reactive oxygen species, and other processes. The GO CC functional enrichment analysis showed that the active target genes of ZRYZD acting on UC were significantly enriched in membrane rafts, cyclin-dependent protein kinase holoheme complex, membrane microdomains, membrane regions, serine/threonine protein kinase complex, and other functions. The GO MF functional enrichment analysis showed that the active target genes of ZRYZD acting on UC were significantly enriched in nuclear receptor activity, ligand-activated transcription factor activity, DNA-binding transcription factor binding, RNA polymerase II-specific DNA-binding transcription factor binding, steroid hormone receptor activity, and other functions (Supplementary File 4). The top 10 GO functional enrichments ranked by q-value are shown in Figure 5(a).

The KEGG pathway enrichment analysis showed that the active target genes of ZRYZD acting on UC were significantly enriched in lipid and atherosclerosis, receptor for advanced glycation end products (AGE)-receptor for AGE (RAGE) signaling pathway in diabetic complications, fluid shear stress and atherosclerosis, hepatitis B, prostate cancer, chemical carcinogenesis-receptor activation, pancreatic cancer, bladder cancer, IL-17 signaling pathway, hepatitis C, and other pathways (Supplementary File 5). The top 30 KEGG pathway enrichments ranked by count values are shown in Figure 5(b).

3.8. Construction of Compound-Target Network. A compound-target network was constructed using Cytoscape software and analyzed using the NetworkAnalyzer tool. As some compounds had no correspondence to an overlapping target gene, the 187 overlapping active target genes correlated with 138 active compounds. There were 325 nodes (138 compound nodes and 187 target gene nodes) and 1,418 edges in the network (Supplementary File 6; Figure 6). Using the NetworkAnalyzer tool, the compounds ranked by the degree in the network are shown in Table S3.

PP, SM, and FC are monarch and minister herbs, which are regarded as the main active herbs in ZRYZD. We selected the compounds in PP, SM, and FC in the network for further analysis, as they can be considered the key compounds in ZRYZD acting on UC. The basic information for the key compounds, ranked by degree, with the 2D structure obtained from the PubChem database, is shown in Table 4.

We organized the data in Table 4, removed the compounds without a structure in the PubChem database, merged the same compounds, and used the most commonly used names in PubChem for the compounds with multiple names. The key compounds included ellipticine, ellagic acid, isoguaiacin, beta-sitosterol, (S)-laudanine, protopine, co-deine, papaverine, cheilanthifoline, noscapine, peraksine,
| Study or Subgroup | Experimental Events | Control Events | Weight (%) | Odds Ratio M-H, Fixed, 95% CI | Year |
|-------------------|---------------------|----------------|------------|-----------------------------|------|
| Yuan JY 2009      | 42 44               | 38 44          | 19.7       | 3.32 [0.63, 17.43]          | 2009 |
| Zhao KH 2010      | 18 19               | 13 16          | 8.5        | 4.15 [0.39, 44.57]         | 2010 |
| Wang L 2015       | 31 34               | 28 40          | 47.9       | 2.43 [0.81, 7.30]         | 2015 |
| Han Y 2019        | 29 32               | 22 31          | 23.9       | 3.95 [0.96, 16.35]         | 2019 |

Total (95% CI) 135 131 100.0 3.11 [1.50, 6.46]

Total events 123 101
Heterogeneity: Chi2 = 0.37, df = 3 (P = 0.95); I2 = 0%
Test for overall effect: Z = 3.05 (P = 0.002)

| Study or Subgroup | Experimental Events | Control Events | Weight (%) | Odds Ratio M-H, Fixed, 95% CI | Year |
|-------------------|---------------------|----------------|------------|-----------------------------|------|
| Yuan JY 2009      | 21 44               | 10 44          | 36.7       | 3.10 [1.24, 7.79]          | 2009 |
| Zhao KH 2010      | 12 19               | 6 16           | 16.8       | 2.86 [0.72, 11.31]         | 2010 |
| Wang L 2015       | 16 40               | 3 40           | 12.6       | 8.22 [2.16, 31.27]         | 2015 |
| Han Y 2019        | 13 32               | 8 31           | 33.9       | 1.97 [0.67, 5.73]         | 2019 |

Total (95% CI) 135 131 100.0 3.32 [1.91, 5.78]

Total events 62 27
Heterogeneity: Chi2 = 2.76, df = 3 (P = 0.43); I2 = 0%
Test for overall effect: Z = 4.26 (P < 0.0001)

Figure 2: Forest plot of clinical efficacy. (a) The fixed effects model was used to merge OR values, and the pooled OR was 3.11 (95% CI 1.50–6.46, P < 0.002). The total effective rate of clinical efficacy was statistically significantly higher in the experimental group than in the control group. (b) The fixed effects model was used to merge OR values, and the pooled OR was 3.32 (95% CI 1.91–5.78, P < 0.0001). The recovery rate of clinical efficacy was significantly higher in the experimental group than that in the control group.

| Study or Subgroup | Experimental Events | Control Events | Weight (%) | Odds Ratio M-H, Fixed, 95% CI | Year |
|-------------------|---------------------|----------------|------------|-----------------------------|------|
| Yuan JY 2009      | 0 44                | 0 44           | No estimable | No estimable | 2009 |
| Han Y 2019        | 1 32                | 6 31           | 43.0       | 0.13 [0.02, 1.19]          | 2019 |
| Dai AC 2021       | 1 45                | 8 45           | 57.0       | 0.11 [0.01, 0.88]         | 2021 |

Total (95% CI) 121 120 100.0 0.12 [0.03, 0.54]

Total events 2 14
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 = 0%
Test for overall effect: Z = 2.76 (P = 0.006)

Figure 3: Forest plot of the incidence of adverse reactions. The fixed effects model was used to merge OR values, and the pooled OR was 0.12 (95% CI 0.03–0.54, P = 0.006). The incidence of adverse reactions was significantly lower in the experimental group than in the control group.

Figure 4: Active target genes of ZRYZD acting on UC. The 277 active target genes of ZRYZD were compared with the 4,798 UC-related genes, and 187 active target genes of ZRYZD acting on UC were identified.
myricanone, norswertianin, tetrahydrofuroguaiacin B, narceine, permethrin, galbacin, cryptogenin, and chebulic acid.

After introducing the key compounds and their 60 corresponding target genes into Cytoscape software, a key compound-target network was constructed. There were 79 cellular response to chemical stress, response to lipopolysaccharide, response to molecule of bacterial origin, response to oxidative stress, response to reactive oxygen species, response to metal ion, cellular response to oxidative stress, response to drug, response to toxic substance, reactive oxygen species metabolic process, membrane raft, membrane microdomain, membrane region, serine/threonine protein kinase complex, protein kinase complex, vesicle lumen, transcription regulator complex, secretory granule lumen, cytoplasmic vesicle lumen, nuclear receptor activity, ligand-activated transcription factor activity, DNA-binding transcription factor binding, RNA polymerase II-specific DNA-binding transcription factor binding, steroid hormone receptor activity, phosphatase binding, steroid binding, antioxidant activity, oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, heme binding.

Figure 5: GO functional enrichment and KEGG pathway enrichment. (a) GO functional enrichment of active target genes. The smaller the q-value, the more significant the enrichment. (b) KEGG pathway enrichment of active target genes. The smaller the q-value and the greater the count, the more significant the enrichment.
Figure 6: Compound-target network. There were 325 nodes (138 compound nodes and 187 target gene nodes) and 1,418 edges in the network. Circles represent active compounds (different colors represent different compounds), diamonds represent active target genes, and the edges represent links between the nodes. The more the connections between the compound and the target gene, the higher the degree value.

| Compound name                  | Compound ID | Pubchem CID | Molecular formula | 2D structure (from PubChem) | Degree | Herb |
|--------------------------------|-------------|-------------|-------------------|-----------------------------|--------|------|
| Ellipticine                    | MOL009135   | 3213        | C17H14N2          | ![Ellipticine](image)       | 18     | FC   |
| Ellagic acid                   | MOL001002   | 5281855     | C14H6O8           | ![Ellagic acid](image)      | 16     | FC   |
| Isoguaiacin                    | MOL009243   | 10314441    | C20H24O4          | ![Isoguaiacin](image)       | 14     | SM   |
| Threo-austrobailignan-5        | MOL009265   | N/A         | N/A               | ![Threo-austrobailignan-5](image) | 13     | SM   |
| Beta-sitosterol                | MOL000358   | 222284      | C29H50O           | ![Beta-sitosterol](image)   | 13     | SM   |
| 5-[[((1S)-6,7-Dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl][methyl]-2-methoxyphenol ((S)-Laudanine) | MOL009328 | 821396 | C26H23NO4 | ![5-[[((1S)-6,7-Dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl][methyl]-2-methoxyphenol ((S)-Laudanine) (image) | 10 | PP   |
| 5-[(2S,3S)-7-Methoxy-3-methyl-5-[(E)-prop-1-enyl]-2,3-dihydrobenzofuran-2-yl]-1,3-benzoxazole (R)-(6-Methoxy-4-quinolyl)-[(2R,4R,5S)-5-vinyquinuclidin-2-yl]methanol | MOL009255 | N/A | N/A | ![5-[(2S,3S)-7-Methoxy-3-methyl-5-[(E)-prop-1-enyl]-2,3-dihydrobenzofuran-2-yl]-1,3-benzoxazole (R)-(6-Methoxy-4-quinolyl)-[(2R,4R,5S)-5-vinyquinuclidin-2-yl]methanol (image) | 10 | SM   |
| 5-[(2S,3S)-7-Methoxy-3-methyl-5-[(E)-prop-1-enyl]-2,3-dihydrobenzofuran-2-yl]-1,3-benzoxazole (R)-(6-Methoxy-4-quinolyl)-[(2R,4R,5S)-5-vinyquinuclidin-2-yl]methanol | MOL009137 | N/A | N/A | ![5-[(2S,3S)-7-Methoxy-3-methyl-5-[(E)-prop-1-enyl]-2,3-dihydrobenzofuran-2-yl]-1,3-benzoxazole (R)-(6-Methoxy-4-quinolyl)-[(2R,4R,5S)-5-vinyquinuclidin-2-yl]methanol (image) | 10 | FC   |
| Fumarine (protopine)           | MOL000787   | 4970        | C20H17NO5         | ![Fumarine (protopine) (image) | 8     | PP   |
| Compound name            | Compound ID | Pubchem CID | Molecular formula | 2D structure (from PubChem) | Degree | Herb |
|--------------------------|-------------|-------------|-------------------|----------------------------|--------|------|
| Codeine                  | MOL006982   | 5284371     | C_{18}H_{21}NO_{3} | ![Image](https://via.placeholder.com/150) | 8      | PP   |
| Papaverine               | MOL006980   | 4680        | C_{20}H_{21}NO_{4} | ![Image](https://via.placeholder.com/150) | 8      | PP   |
| Cheilanthifoline         | MOL009149   | 5117621     | C_{19}H_{19}NO_{4} | ![Image](https://via.placeholder.com/150) | 7      | FC   |
| Noscapine                | MOL009330   | 275196      | C_{22}H_{23}NO_{7} | ![Image](https://via.placeholder.com/150) | 6      | PP   |
| Peraksine                | MOL009136   | 78146432    | C_{19}H_{22}N_{2}O_{2} | ![Image](https://via.placeholder.com/150) | 6      | FC   |
| Noskapin (noscapine)     | MOL009327   | 275196      | C_{22}H_{23}NO_{7} | ![Image](https://via.placeholder.com/150) | 5      | PP   |
| Saucernetindiol          | MOL009263   | N/A         | N/A               | ![Image](https://via.placeholder.com/150) | 5      | SM   |
| Erythroculine            | MOL009335   | N/A         | N/A               | ![Image](https://via.placeholder.com/150) | 4      | PP   |
| Myricanone               | MOL009331   | 161748      | C_{21}H_{24}O_{5}  | ![Image](https://via.placeholder.com/150) | 4      | PP   |
| Norswertianin            | MOL009338   | 5281658     | C_{13}H_{8}O_{6}   | ![Image](https://via.placeholder.com/150) | 3      | PP   |
| Tetrahydrofuroguaiacin B| MOL009264   | 13870572    | C_{20}H_{24}O_{5}  | ![Image](https://via.placeholder.com/150) | 3      | SM   |
| Narcein (narceine)       | MOL009329   | 8564        | C_{23}H_{25}NO_{8} | ![Image](https://via.placeholder.com/150) | 2      | PP   |
| Kudos (permethrin)       | MOL009259   | 40326       | C_{21}H_{20}Cl_{2}O_{3} | ![Image](https://via.placeholder.com/150) | 2      | SM   |
| Galbacin                 | MOL009254   | 234441      | C_{20}H_{20}O_{5}  | ![Image](https://via.placeholder.com/150) | 2      | SM   |
nodes (19 compound nodes and 60 target gene nodes) and 132 edges in the network (Supplementary File 7; Figure 7). Using the NetworkAnalyzer tool, the top six target genes, ranked by degree, were PTGS2, PTGS1, ADRA1B, RXRA, OPRM1, and SLC6A4.

3.9. Construction of the PPI Network. The 60 corresponding target genes were mapped into the STRING database, and the PPI network was obtained. In the network, 59 target proteins had interactions, and 456 edges represented the interactions between the proteins when the lowest interaction score was set to 0.40 (Supplementary File 8; Figure 8).

The top 10 target genes ranked by the degree in the PPI network are shown in Table 5; these can be considered the key target proteins of ZRYZD acting on UC.

3.10. Molecular Docking Analysis. The 3D structures of the compounds were obtained from the PubChem database, and the target proteins from the RCSB PDB database. Molecular docking simulations of the target proteins and their corresponding compounds were performed using AutoDock Tool and AutoDock Vina software. The binding of the target proteins with their corresponding compounds was analyzed using molecular docking. The molecular docking simulations of TP53-ellipticine are shown in Figure 9.

4. Discussion

According to TCM theory, UC belongs to the category of “dysentery” and is characterized by dampness and heat accumulation, qi and blood disorder, and visceral food accumulation. The disease location of UC is in the intestine, and kidney qi insufficiency, spleen deficiency, endogenous dampness, and heat are considered the primary causes of this disease. Accordingly, TCM theory suggests that the treatment of patients should be based on supplementing the spleen and kidney, invigorating qi and warming yang [30]. From the perspective of modern medicine, the pathogenesis of UC is primarily related to chronic nonspecific inflammation, which is the result of the interaction of the host response, genetic factors, and immune imbalance.

ZRYZD, which consists of PP, SM, FC, CC, RC, RAM, RAS, RPA, RA, and RG as the main components, has the effect of consolidating and astringing the intestine, and nourishing the spleen and kidney. PP, SM and FC, which are considered monarch and minister herbs, can be used as intestinal astringents to stop diarrhea. CC, RC, and RAM can warm the spleen and kidney. RAS, RPA, and RA can regulate qi and blood. RG can replenish qi and reconcile all the other herbs [10].

Several clinical studies have reported that ZRYZD improves clinical outcomes in the treatment of UC. Therefore, we first evaluated the effectiveness and safety of ZRYZD for UC using an evidence-based analytical approach. We screened five RCTs that investigated the efficacy of ZRYZD for UC and performed a meta-analysis. Meta-analysis indicated that the total effective rate and recovery rate of clinical efficacy were statistically significantly higher in the experimental group than those in the control group and that the incidence of adverse reactions was significantly lower in the experimental group than that in the control group. This analysis demonstrates the effectiveness and safety of ZRYZD for UC from the perspective of evidence-based medicine, providing a foundation for further investigation of its pharmacological mechanisms of action. Furthermore, meta-analysis indicated that serum IL-6 and TNF-α were significantly lower in the experimental group compared with the control group, suggesting that the therapeutic effectiveness of ZRYZD for UC may be associated with a reduction in inflammation.

Network pharmacology is widely used in the study of TCM. The network pharmacology approach and platform could make the systematic study of herbal medicines achievable and advance pharmacodynamic substance discovery and could also provide a new strategy for translating TCM from an experience-based to an evidence-based medical system [31, 32]. Recently, guidelines for the network pharmacology evaluation method were drafted, allowing many technical and analysis-related problems to be resolved, permitting a more scientific approach for TCM network pharmacology research [33]. Network pharmacology advocates a multicomponent therapeutic approach, which is consistent with the multicomponent, multitarget, and multipathway characteristics of TCM [34, 35]. Hence, we used the network pharmacology approach to investigate the pharmacological mechanisms of action of ZRYZD for UC. In this study, 187 active target genes of ZRYZD acting on UC

| Compound name   | Compound ID | Pubchem CID | Molecular formula | 2D structure (from PubChem) | Degree | Herb |
|-----------------|-------------|-------------|-------------------|-----------------------------|--------|------|
| Cryptogenin     | MOL009324   | 21117640    | C_{27}H_{42}O_{4}  | ![2D structure](image)       | 1      | PP   |
| Chebulic acid   | MOL006826   | 71308174    | C_{14}H_{12}O_{11} | ![2D structure](image)     | 1      | FC   |

ZRYZD: Zhen Ren Yang Zang decoction; UC: ulcerative colitis; PP: *pericarpium papaveris*; SM: *semen myristicae*; FC: *fructus chebulae*. 

**Table 4: Continued.**
were identified. The GO BP functional enrichment analysis suggested that the active target genes of ZRYZD acting on UC were significantly enriched in the cellular response to chemical stress, response to lipopolysaccharides, response to molecules of bacterial origin, and other processes. The GO CC functional enrichment analysis revealed that the active target genes of ZRYZD acting on UC were significantly enriched in membrane rafts, cyclin-dependent protein kinase holoenzyme complex, membrane microdomains, and other functions. The GO MF functional enrichment analysis showed that the active target genes of ZRYZD acting on UC were significantly enriched in nuclear receptor activity, ligand-activated transcription factor activity, DNA-binding transcription factor binding, and other functions. These functions are closely related to inflammation and immune regulation, which are in turn closely related to the etiopathogenesis of UC [36–38].

The KEGG pathway enrichment analysis showed that many pathways were closely related to the pathogenesis of UC. The primary pathways included lipid and atherosclerosis, AGE-RAGE signaling pathway in diabetic complications, fluid shear stress and atherosclerosis, hepatitis B, prostate cancer, chemical carcinogenesis-receptor activation, pancreatic cancer, bladder cancer, IL-17 signaling pathway, and hepatitis C. Some of these pathways have been reported to be closely related to UC. IL-17 is upregulated in inflamed mucosa from UC patients, and IL-17 levels in peripheral blood mononuclear cells are correlated with disease severity in UC patients [39]. IL-17 is produced mainly by T helper 17 cells and is considered to be a key pathophysiological mediator and plays an important role in regulating the intestinal immune response [40]. In UC, AGE and IL-17 are highly expressed and participate in nuclear factor-κB pathway activation [41, 42]. These observations suggest that ZRYZD may ameliorate UC via multiple pathways related to inflammation and the immune response. These pathways and relevant target genes are worthy of further study.

A network of a compound-target network was constructed, and the compounds of ZRYZD acting on UC were identified. The 187 overlapping active target genes correlated with 138 active compounds. We found that these 138 compounds correspond to each herb in ZRYZD, and we can argue that every herb in ZRYZD plays a role in acting on UC. We also found that the importance of active compounds in PP, SM, and FC in the compound-target network is obvious. These findings are in agreement with TCM theory. PP, SM, and FC are monarch and minister herbs and are regarded as the main active herbs in ZRYZD. Therefore, we selected the compounds in PP, SM, and FC in the network for further study, and we constructed a key compound-target network to identify the key compounds. The key compounds were ellipticine, ellagic acid, isoguaiacin, beta-sitosterol, (S)-laudanine, protopine, codeine, papaverine, cheilanthifoline, noscapine, peraksine, myricanone, norswertianin, tetrahydrofuroguaiacin B, narceine, permethrin, galbacin, cryptogenin, and chebulic acid. Ficus carica aqueous extract containing ellagic acid can ameliorate UC-associated acute functional gastrointestinal disorder in rats [43]; A study verified the ethnomedical use of Cornus mas L. for the treatment of UC, in which ellagic acid was identified in extracts and its amount quantified [44]. A study provided evidence for the therapeutic effectiveness of Canna x generalis L.H. Bailey rhizome extract for the treatment of UC.

Figure 7: Key compound-target network. There were 79 nodes (19 compound nodes and 60 target gene nodes) and 132 edges in the network. The more the connections between the compound and the target gene, the higher the degree value.
and discovered beta-sitosterol as one of the major identified constituents [45], which was shown to improve experimental colitis in mice by targeting pathogenic bacteria [46]. Prostaglandin synthetase activity in rectal biopsy specimens from patients with UC has been shown to fall on treatment with sulfasalazine, local steroids, and codeine phosphate [47]. Papaverine adjuvant can treat microcirculatory disturbance in severe UC complicated with cytomegalovirus infection [48]. These studies reveal an effect on the regulation of inflammation and immune function. Therefore, the action of ZRYZD on UC could be the result of the interaction of multiple compounds. However, there are only a few studies on the effect of individual constituent compounds on UC, which therefore requires further investigation.

The PPI network showed that the action of ZRYZD on UC was related to multiple targets. The key target proteins were TP53, VEGFA, JUN, CASP3, ESR1, PTGS2, MMP9, PPARG, BCL2L1, and CASP8. A previous study showed that alterations in p53 may be an early biomarker of a progressor colon and that p53 is upregulated early in UC-related carcinogenesis [49]. In UC patients, p53 enhances VEGF expression and subsequent production of proinflammatory TNF-α and IL-6 [50]. Berberis lycium fruit extract can attenuate oxidative/inflammatory stress and promote mucosal healing by downregulating NF-κB/c-Jun/MAPK signaling and augmenting splenic Treg proliferation in a murine model of dextran sulfate sodium-induced UC [51]. Analysis of biopsies from UC patients and normal controls demonstrates that disease-associated occludin downregulation is accompanied by and correlated with reduced caspase-3 expression [52]. Inactivation through methylation of the putative tumor suppressor gene ESR1 may not be associated with colorectal carcinogenesis in UC [53]. Amentoflavone inhibits PTGS2 expression and
modulates cytokine profile and NF-κB signal transduction pathways in rats with UC [54]. In patients with active UC, MMP2, MMP9, and inflammatory factors are significantly increased [55]. Gliclazide attenuates acetic acid-induced colitis via the modulation of PPARG, NF-κB, and MAPK signaling pathways [56]. HSPA6 is a UC susceptibility factor that is induced by cigarette smoke and protects intestinal epithelial cells by stabilizing antiapoptotic Bcl-XL [57]. Cyclosporine upregulates transforming growth factor-β in colonic tissue and inhibits caspase-8 activity in epithelial cells [58]. These studies demonstrate the relationship between these genes and UC, facilitating the further exploration of the therapeutic mechanisms of action.

Molecular docking was also performed to analyze specific interactions between key compounds and their protein targets, which could improve the robustness of the network model. The preliminary molecular docking results showed that the key active compounds in ZRYZD had high binding activities with their corresponding protein targets. These active compounds may mediate the therapeutic action of ZRYZD for UC via related signaling pathways. Compounds related to the corresponding target proteins can also be investigated in future studies.

The pharmacological mechanisms of action of ZRYZD for UC were investigated using a network pharmacology approach, and the binding of the target to the corresponding compound was analyzed using molecular docking. However,
there are some limitations to using these approaches. First, the active compounds and target genes of ZRYZD were searched using the TC MSP database. The screening criteria and definition of the active compounds were fixed, and the UC-related genes were obtained from the GeneCards database. Although these databases are currently relatively comprehensive, some compounds and target genes may have been omitted. In addition, not all the compounds that enter the circulation may contribute to the efficacy of ZRYZD. Second, while the GO functional enrichment and KEGG pathway enrichment analyses were performed, and a PPI network was constructed to investigate the target genes and pathways of ZRYZD acting on UC, the potential target genes and pathways require further study using empirical analyses. Third, only preliminary molecular docking analyses were conducted in this study, and more in-depth analyses of the molecular docking of small-molecule compounds and macromolecular protein targets are needed.

5. Conclusion

The effectiveness and safety of ZRYZD for the treatment of UC were evaluated with an evidence-based approach. Using network pharmacology, we investigated the relationships between the active compounds, target genes, and signaling pathways, which revealed the involvement of multiple compounds, multiple targets, and multiple pathways. Finally, key compounds and their predicted target proteins were used for molecular docking analyses, which provided further evidence that these compounds may be important mediators of the therapeutic action of ZRYZD against UC.

Data Availability

The data used to support this study are included in the supplementary files.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Guosheng Xing, Yufeng Zhang, Mingxing Hou, and Haibing Hua conceived and designed the study and wrote the manuscript. Guosheng Xing, Xinlin Wu, Hua Wang, Yan Liu, and Zhen Zhang were responsible for data collation and extraction and performed the data analysis. Mingxing Hou and Haibing Hua performed supervision and project administration. Guosheng Xing, Yufeng Zhang, and Haibing Hua performed the revision of the article. All the authors read and approved the final manuscript. Guosheng Xing and Yufeng Zhang contributed equally to the article.

Acknowledgments

The authors would like to acknowledge the web database platform and software for data analyses. This study was partially supported by the Science and Technology Project of Inner Mongolia Medical University (YKD2020KJBW(LH) 014) and the Inner Mongolia Natural Science Foundation (2021MS08097) to Xing, and the fifth phase of the “333 project” scientific research funded project to Hua. The authors thank Barry Patel, PhD, from Liwen Bianji (Edanz) (https://www.liwenbianji.cn/), for editing the English text of a draft of this manuscript.

Supplementary Materials

Figure S1: Risk of bias graph. Figure S2: risk of bias summary. Figure S3: forest plot of comparison of serum cytokines. Figure S4: forest plot of comparison of the total syndrome score of TCM. Table S1: basic information on the active compounds in ZRYZD. Table S2: gene symbols and entrezID of active target genes. Table S3: compounds ranked by the degree in the network. Supplementary File 1: compounds of ZRYZD from TC MSP. Supplementary File 2: corresponding target genes of ZRYZD. Supplementary File 3: UC-related target genes. Supplementary File 4: GO functional enrichment analysis. Supplementary File 5: KEGG pathway enrichment analysis. Supplementary File 6: data of compound-target networks. Supplementary File 7: data of key compound-target networks. Supplementary File 8: data of PPI network. (Supplementary Materials)

References

[1] R. Ungaro, S. Mehandru, P. B. Allen, L. Peyrin-Biroulet, and J.-F. Colombel, “Ulcerative colitis,” The Lancet, vol. 389, no. 10080, pp. 1756–1770, 2017.
[2] S. Danese and C. Fiocchi, “Ulcerative colitis,” New England Journal of Medicine, vol. 365, no. 18, pp. 1713–1725, 2011.
[3] T. Tanaka, T. Kobunai, Y. Yamamoto et al., “Assessment of the changes in mitochondrial gene polymorphism in ulcerative colitis and the etiology of ulcerative colitis-associated colorectal cancer,” Anticancer Research, vol. 40, no. 1, pp. 101–107, 2020.
[4] C. Bello, J. Belaiche, E. Louis, and C. Reenaers, “Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids,” Journal of Crohns & Colitis, vol. 5, no. 3, pp. 196–202, 2011.
[5] M. Salice, F. Rizzello, C. Calabrese, L. Calandrini, and P. Gionchetti, “A current overview of corticosteroid use in active ulcerative colitis,” Expert Review of Gastroenterology & Hepatology, vol. 13, no. 6, pp. 557–561, 2019.
[6] X. Zhou, R. Gao, X. Zhang, T. Shen, and K. Xu, “Efficacy of xianglian pill for antibiotic-associated diarrhea: a protocol for systematic review and meta-analysis,” Traditional Medicine Research, vol. 6, no. 5, p. 43, 2021.
[7] P. Wan, H. Chen, Y. Guo, and A. P. Bai, “Advances in treatment of ulcerative colitis with herbs: from bench to bedside,” World Journal of Gastroenterology, vol. 20, no. 39, pp. 14999–14104, 2014.
[8] Z. Shen, Q. Zhou, Y. Ni, W. He, H. Shen, and L. Zhu, “Traditional Chinese medicine for mild-to-moderate ulcerative colitis: protocol for a network meta-analysis of randomized controlled trials,” Medicine (Baltimore), vol. 98, no. 33, Article ID e16881, 2019.
[9] Z. X. Yan, Y. M. Liu, T. Ma et al., “Efficacy and safety of retention enema with traditional Chinese medicine for ulcerative colitis: a meta-analysis of randomized controlled
trials,” Complementary Therapies in Clinical Practice, vol. 42, Article ID 101278, 2021.

[10] J. Qi, Y. N. Tang, Y. F. Zhang, Q. Q. Xia, and W. L. Jiang, “Zhenren yangzang decoction in treatment of ulcerative colitis: a systematic review,” Liaoning Journal of Traditional Chinese Medicine, vol. 43, no. 1, pp. 16–19, 2016.

[11] J. Y. Yuan and D. H. Li, “Clinical observation of 44 cases of zhenren yangzang decoction in treatment of ulcerative colitis,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 24, no. 51, pp. 117–118, 2009.

[12] K. H. Zhao, “Warming and astringent method treating 19 cases of ulcerative colitis with deficiency of spleen and kidney yang,” Henan Traditional Chinese Medicine, vol. 30, no. 1, pp. 63-64, 2010.

[13] H. Wang, S. H. Li, Y. Zhang et al., “Therapeutic efficacy and mechanism of Zhenren yangzang decoction in rats with experimental ulcerative colitis,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 9, pp. 15254–15261, 2015.

[14] J. P. Higgins, D. G. Altman, P. Jüni et al., “The Cochrane collaboration’s tool for assessing risk of bias in randomised trials,” BMJ (Clinical research ed.), vol. 343, Article ID d5928, 2011.

[15] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.

[16] Q. Xia, M. Liu, H. Li, L. Tian, J. Qi, and Y. Zhang, “Network pharmacology strategy to investigate the pharmacological mechanism of Huang Qi Xi Xion decoction on cough variant asthma and evidence-based medicine approach validation,” Evidence-based Complementary and Alternative Medicine: ECAM, vol. 2020, Article ID 3829092, 15 pages, 2020.

[17] W. Jiang, Y. Zhang, M. Liu et al., “A network pharmacology approach to explore the mechanism of kanganhu decoction in the treatment of coronavirus disease 2019 with preliminary verification,” TMR Integrative Medicine, vol. 5, Article ID e21025, 2021.

[18] C. T. UniProt, "UniProt: the universal protein knowledge-base," Nucleic Acids Research, vol. 46, no. 5, p. 2699, 2018.

[19] G. Stelzer, N. Rosen, I. Plaschkes et al., “The genecards suite: from gene data mining to disease genome sequence analyses,” Current Protocols in Bioinformatics, vol. 54, pp. 1–33, 2016.

[20] G. Yu, L.-G. Wang, Y. Han, and Q.-Y. He, “ClusterProfiler: an R package for comparing biological themes among gene clusters,” OMICS: A Journal of Integrative Biology, vol. 16, no. 5, pp. 284–287, 2012.

[21] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.

[22] D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.

[23] M. F. Sanner, “Python: a programming language for software integration and development,” Journal of Molecular Graphics & Modelling, vol. 17, no. 1, pp. 57–61, 1999.

[24] D. Jiang, X. Wang, L. Tian, and Y. Zhang, “Network pharmacology strategy to investigate the pharmacological mechanism of siwu decoction on primary dysmenorrhea and molecular docking verification,” Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 6662247, 13 pages, 2021.

[25] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002.

[26] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003.

[27] L. Wang and D. M. Liu, “Treatment of 40 cases of ulcerative colitis with deficiency of spleen and kidney yang by zhenren yangzang decoction and sini decoction,” Hunan Journal of Traditional Chinese Medicine, vol. 31, no. 10, pp. 43–44, 2015.

[28] Y. Han, Y. Zhang, D. F. Yang et al., “Clinical efficacy of dongbin organ-nourishing decoction in ulcerative colitis patients regarding disease activity and serum inflammatory cytokines,” Journal of Clinical and Experimental Medicine, vol. 18, no. 9, pp. 936–939, 2019.

[29] A. C. Dai, L. J. Chu, C. X. Zhang, N. H. Guo, Y. Y. Liang, and Z. Y. Wu, “Effect of zhenren yangzang decoction on micro inflammatory state and disease degree of ulcerative colitis,” Journal of Practical Traditional Chinese Medicine, vol. 37, no. 7, pp. 1118-1119, 2021.

[30] Z. F. Chen and H. Y. Liu, “Research progress of traditional Chinese medicine in ulcerative colitis,” Journal of Changchun University of Chinese Medicine, vol. 34, no. 1, pp. 196–198, 2018.

[31] B. Zhang, X. Wang, and S. Li, “An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin,” Evidence-based Complementary and Alternative Medicine: ECAM, vol. 2013, Article ID 456747, 12 pages, 2013.

[32] S. Li and B. Zhang, “Traditional Chinese medicine network pharmacology: theory, methodology and application,” Chinese Journal of Natural Medicines, vol. 11, no. 2, pp. 110–120, 2013.

[33] S. Li, “Network pharmacology evaluation method guidance-draft,” World Journal of Traditional Chinese Medicine, vol. 7, no. 1, pp. 146–154, 2021.

[34] J. Yuan, J. Hao, and D. Chen, “Network pharmacology: an important breakthrough in traditional Chinese medicine research,” TMR Integrative Medicine, vol. 2, no. 3, pp. 92–98, 2018.

[35] T.-T. Luo, Y. Lu, S.-K. Yan, X. Xiao, X.-L. Rong, and J. Guo, “Network pharmacology in research of Chinese medicine formula: methodology, application and prospective,” Chinese Journal of Integrative Medicine, vol. 26, no. 1, pp. 72–80, 2020.

[36] M. Wei, H. Li, Q. Li et al., “Based on network pharmacology to explore the molecular targets and mechanisms of geng qinlian decoction for the treatment of ulcerative colitis,” Biomed Research International, vol. 2020, Article ID 5217405, 10 pages, 2020.

[37] L. Xu, J. Zhang, Y. Wang, Z. Zhang, F. Wang, and X. Tang, “Uncovering the mechanism of Ge-Gen-Qin-Li decoction for treating ulcerative colitis based on network pharmacology and molecular docking verification,” Bioscience Reports, vol. 41, no. 2, 2021.

[38] B. Shi, S. Liu, A. Huang et al., “Revealing the mechanism of friedelin in the treatment of ulcerative colitis based on network pharmacology and experimental verification,” Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 4451779, 14 pages, 2021.
Evidence-Based Complementary and Alternative Medicine

[40] A. Ueno, L. Jeffery, T. Kobayashi, T. Hibi, S. Ghosh, and H. Jijon, “Th17 plasticity and its relevance to inflammatory bowel disease,” Journal of Autoimmunity, vol. 87, pp. 38–49, 2018.

[41] J. Tobon-Velasco, E. Cuevas, and M. Torres-Ramos, “Receptor for AGEs (RAGE) as mediator of NF-κB pathway activation in neuroinflammation and oxidative stress,” CNS & Neurological Disorders-Drug Targets, vol. 13, no. 9, pp. 1615–1626, 2014.

[42] H. Zhang, B. Xia, J. Li et al., “Expression and clinical significance of IL-17 and IL-17 receptor in ulcerative colitis,” Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 36, no. 1, pp. 37–40, 2016.

[43] K. Rtibi, D. Grami, D. Wannes et al., “Ficus carica aqueous extract alleviates delayed gastric emptying and recovers ulcerative colitis-enhanced acute functional gastrointestinal disorders in rats,” Journal of Ethnopharmacology, vol. 224, pp. 242–249, 2018.

[44] I. Sütar, C. K. Cevik, A. O. Çeribası, and A. Gökbulut, “Healing effects of cornus mas L. in experimentally induced ulcerative colitis in rats: from ethnobotany to pharmacology,” Journal of Ethnopharmacology, vol. 248, Article ID 112322, 2020.

[45] T. N. Mahmoud, W. H. El-Maadawy, Z. A. Kandil, H. Khalil, N. M. El-Fiky, and A. T. El, “Canna x generalis L.H. bailey rhizome extract ameliorates dextran sulfate sodium-induced colitis via modulating intestinal mucosal dysfunction, oxidative stress, inflammation, and TLR4/NF-B and NLRP3 inflamasome pathways,” Journal of Ethnopharmacology, vol. 269, Article ID 113670, 2021.

[46] K. Ding, Y. Y. Tan, Y. Ding et al., "β-sitosterol improves experimental colitis in mice with a target against pathogenic bacteria," Journal of Cellular Biochemistry, vol. 120, no. 4, pp. 5687–5694, 2019.

[47] P. R. Smith, D. J. Dawson, and C. H. Swan, "Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone," Gut, vol. 20, no. 9, pp. 802–805, 1979.

[48] Y. Tian, Y. Zheng, J. Dong, J. Zhang, and H. Wang, "Papaverine adjuvant therapy for microcirculatory disturbance in severe ulcerative colitis complicated with CMV infection: a case report," Clinical Journal of Gastroenterology, vol. 12, no. 5, pp. 407–413, 2019.

[49] M. Friis-Ottessen, E. Burum-Auensen, A. R. Schjolberg et al., “TP53/p53 alterations and aurora A expression in progressor and non-progressor colectomies from patients with longstanding ulcerative colitis,” International Journal of Molecular Medicine, vol. 35, no. 1, pp. 24–30, 2015.

[50] N. D. Zdravkovic, I. P. Jovanovic, G. D. Radosavljevic et al., "Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinoma," International Journal of Medical Sciences, vol. 11, no. 9, pp. 936–947, 2014.

[51] A. Sharma, N. V. Tirpude, P. M. Kulurkar, R. Sharma, and Y. Padwad, "Berberis lycium fruit extract attenuates oxi-inflamatory stress and promotes mucosal healing by mitigating NF-κB/c-Jun/MAPKs signalling and augmenting splenic treg proliferation in a murine model of dextran sulphate sodium-induced ulcerative colitis," European Journal of Nutrition, vol. 59, no. 6, pp. 2663–2681, 2020.

[52] W.-T. Kuo, L. Shen, L. Zuo et al., "Inflammation-induced occludin downregulation limits epithelial apoptosis by suppressing caspase-3 expression," Gastroenterology, vol. 157, no. 5, pp. 1323–1337, 2019.

[53] R. P. Arasaradnam, K. Khoo, M. Bradburn, J. Mathers, and S. Kelly, "DNA methylation of ESR-1 and N-33 in colorectal mucosa of patients with ulcerative colitis (UC)," Epigenetics, vol. 5, no. 5, pp. 422–426, 2010.

[54] K. M. Sakhivel and C. Guruvayoorappan, "Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-κB signal transduction pathways in rats with ulcerative colitis," International Immunopharmacology, vol. 17, no. 3, pp. 907–916, 2013.

[55] X. Bai, G. Bai, L. Tang, L. Liu, Y. Li, and W. Jiang, "Changes in MMP-2, MMP-9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis," Experimental and Therapeutic Medicine, vol. 20, no. 1, pp. 269–274, 2020.

[56] E. A. Arafa, W. R. Mohamed, D. M. Zaher, and H. A. Omar, "Gliclazide attenuates acetic acid-induced colitis via the modulation of PPAR gamma, NF-kappaB and MAPK signaling pathways," Toxicology and Applied Pharmacology, vol. 391, Article ID 114919, 2020.

[57] A. Regeling, F. Imhann, H. H. Volders et al., “HSPA6 is an ulcerative colitis susceptibility factor that is induced by cigarette smoke and protects intestinal epithelial cells by stabilizing anti-apoptotic Bcl-XL,” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1862, no. 4, pp. 788–796, 2016.

[58] Y. Satoh, Y. Ishiguro, H. Sakuraba et al., "Cyclosporine regulates intestinal epithelial apoptosis via TGF-β-related signaling," American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 297, no. 3, pp. G514–G519, 2009.